Olaparib is a compound that effectively inhibits PARP1 and PARP2, binding to the catalytic domain and preventing the transfer of ADP-ribose units from NAD + to target proteins, thus lowering NAD + consumption 160,161
Ask your prescriber about checking your BMP (basic metabolic panel) periodically, especially during dose escalation phases
Phase 1b (CT-388, 24 weeks): Phase 2 (CT-388 up to 24 mg, 48 weeks): GI AEs described as "mild-to-moderate" and "generally consistent with incretin class" Discontinuation due to AEs: 5.9% (vs 1.3% placebo) Weight loss: 22.5% placebo-adjusted at 48 weeks Key characteristics: Phase 1b showed very high absolute GI rates during titration, but these declined substantially during maintenance Phase 2 data showed a much more favorable tolerability profile with a low discontinuation rate of 5.9% The signal-biased design appears to provide sustained receptor activation without desensitization Despite high initial GI rates, very few patients discontinued, suggesting events were transient and manageable Phase 3 (ENITH program) planned for 2026 Bioglutide (NA-931)# Bioglutide is the first oral quadruple receptor agonist (GLP-1, GIP, glucagon, and IGF-1), developed by Biomed Industries
Proper reconstitution, refrigeration, needle handling, and disposal reduce contamination risk
Microbiome and nutraceutical GLP-1 modulation represents an emerging but still nascent category, with early patents [36] and scientific exploration [37] but minimal commercial traction to date
